跳至主要内容
临床试验/NCT05004012
NCT05004012进行中(未招募)不适用

AnX/Ankon Navicam Magnetically Controlled Capsule Endoscopy Feasibility Study in Gastric Motility

University of California, Los Angeles2 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2021年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
17
试验地点
2
主要终点
Number and location of luminal transit markers in the antrum, fundus, and overall

研究概览

简要总结

This is a feasibility study to assess the utility of magnetically controlled capsule endoscopy in the evaluation of gastroparesis and functional dyspepsia

详细描述

Gastroparesis and functional dyspepsia can both present with abdominal pain, dyspepsia, nausea, emesis, or early satiety. Gastroparesis is a syndrome defined as delayed gastric emptying. Functional dyspepsia is a symptom-based diagnosis in which the pathophysiology is multifactorial. Delayed gastric emptying is present in 25-35% of patients with functional dyspepsia. The study investigators propose the Navicam magnetically controlled capsule endoscopy (MCCE) system as a potential new method of evaluating gastric motility disorders. The MCCE is FDA approved for visualization of the stomach. The ability to visualize gastric peristalsis in real time, without interference from an endoscope, has never been demonstrated. The MCCE system could allow physicians to evaluate gastric motility with a test that has clear advantages over the current methods: it is fast, non-invasive, and has no radiation exposure, has artificial intelligence (AI) capabilities, while at the same time provides a visual assessment of the gastric anatomy. In this pilot feasibility study, the study investigators plan to enroll 5 male and female adult healthy volunteers, 5 male and female patients with gastroparesis, 5 male and female patients with functional dyspepsia (epigastric pain syndrome and/or postprandial distress syndrome with or without gastric emptying delay), and 2 patients with gastroparesis who have undergone a G-POEM procedure. The study investigators will compare gastric motor patterns in the different sections of the stomach and symptoms during fasting and a sham meal between groups.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • Another active disorder or treatment which could explain or contribute to symptoms in the opinion of the Investigator (including but not limited to gastric malignancy, neurological disorder, or heavy doses of strong anticholinergics).
  • Gastrectomy, fundoplication, vagotomy, bariatric surgery, post-surgical cause of gastroparesis, or gastric stimulation device surgically implanted within the last year. Prior G-POEM procedure for gastroparesis is allowed for the group of post-G-POEM study subjects.
  • Dysphagia, swallowing disorder
  • Suspected bowel obstruction or perforation
  • Gastric or parenteral feeding within 4 weeks of screening
  • Pregnancy or nursing
  • History of an eating disorder within 2 years of screening
  • Recent history (within six months of screening) of Alcohol Use Disorder or Substance Use Disorder as defined in DSM-
  • Uncontrolled thyroid disease
  • Unstable cardiac, respiratory, hepatic or renal disease
  • Evidence of uncontrolled blood glucose (including HbA1C >9 or metabolic crisis in past 60 days).
  • Use of prohibited medication or medication with anti-nausea, antiemetic, neuromodulating, or prokinetic effect within 2 weeks of the screening visit EXCEPT when administered on a stable daily dosing schedule (stable for at least 1 month prior to the screening visit).
  • Use of as needed or daily opioids within the past 1 month.
  • Pyloric injection of neurotoxins (e.g. botulinum type A or B) within 3 months of the Screening visit.
  • Altered mental status (e.g., hepatic encephalopathy) that limits the ability to swallow a capsule
  • Expected to have Magnetic Resonance Imaging (MRI) examination within 30 days.
  • No reliable contact information - no phone, no permanent address.
  • Pacemaker or ICD
  • Inability to avoid using the bathroom for urination and/or bowel movements for the duration of the study.
  • Metal Implant (ie metal hip arthroplasty, surgical mesh, coronary or arterial stent)
  • Prior bowel surgery
  • Severe claustrophobia
  • Any other reason as determined by the Investigator which may lead to an unfavorable risk-benefit of study participation, may interfere with study compliance, or may confound study results.

结局指标

主要结局

Number and location of luminal transit markers in the antrum, fundus, and overall

时间窗: Through study completion, an average of 1 year

Physiologic parameter measuring the number and location of luminal transit markers in the stomach

Largest diameter of the pylorus

时间窗: Through study completion, an average of 1 year

Physiologic parameter measuring the diameter of the pylorus

Procedure related adverse events

时间窗: Through study completion, an average of 1 year

Procedure related adverse events during or after the study session

Dyspepsia Severity Scale symptom ratings at baseline and during the study at timepoints with discomfort if present.

时间窗: Through study completion, an average of 1 year

Evaluating the dyspepsia Severity Scale symptom ratings (range of score 0-20) at baseline and during the study at timepoints with discomfort if present.

Frequency and direction of contractions

时间窗: Through study completion, an average of 1 year

Physiologic parameter measuring the frequency and direction of stomach contractions

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lin Chang, MD

Principal Investigator

University of California, Los Angeles

研究点 (2)

Loading locations...

相似试验

Magnetically Controlled Capsule Endoscopy... | 临床试验